Anika Therapeutics Inc (ANIK)vsTeva Pharma Industries Ltd ADR (TEVA)
ANIK
Anika Therapeutics Inc
$14.48
-2.10%
HEALTHCARE · Cap: $191.73M
TEVA
Teva Pharma Industries Ltd ADR
$34.43
-2.71%
HEALTHCARE · Cap: $40.32B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 14822% more annual revenue ($17.35B vs $116.26M). TEVA leads profitability with a 9.0% profit margin vs -9.5%. TEVA appears more attractively valued with a PEG of 0.85. TEVA earns a higher WallStSmart Score of 66/100 (B-).
ANIK
Hold38
out of 100
Grade: F
TEVA
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.4%
Fair Value
$32.46
Current Price
$14.48
$17.98 discount
Intrinsic value data unavailable for TEVA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Earnings expanding 72.2% YoY
Growing faster than its price suggests
Areas to Watch
Smaller company, higher risk/reward
Expensive relative to growth rate
ROE of -8.3% — below average capital efficiency
Earnings declined 50.5%
Moderate valuation
2.3% revenue growth
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ANIK
The strongest argument for ANIK centers on Price/Book, Altman Z-Score, Debt/Equity. Revenue growth of 13.2% demonstrates continued momentum.
Bull Case : TEVA
The strongest argument for TEVA centers on EPS Growth, PEG Ratio. PEG of 0.85 suggests the stock is reasonably priced for its growth.
Bear Case : ANIK
The primary concerns for ANIK are Market Cap, PEG Ratio, Return on Equity.
Bear Case : TEVA
The primary concerns for TEVA are P/E Ratio, Revenue Growth, Free Cash Flow. Debt-to-equity of 2.05 is elevated, increasing financial risk.
Key Dynamics to Monitor
ANIK profiles as a turnaround stock while TEVA is a value play — different risk/reward profiles.
TEVA carries more volatility with a beta of 0.85 — expect wider price swings.
ANIK is growing revenue faster at 13.2% — sustainability is the question.
ANIK generates stronger free cash flow (-6M), providing more financial flexibility.
Bottom Line
TEVA scores higher overall (66/100 vs 38/100). ANIK offers better value entry with a 68.4% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Anika Therapeutics Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Anika Therapeutics, Inc., is a joint preservation company in the United States, Europe, and internationally. The company is headquartered in Bedford, Massachusetts.
Visit Website →Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?